The present invention relates to a compound of general formula (I): said compound being as defined in claim (1). The invention also relates to a pharmaceutical composition comprising: -a compound of general formula (I) as defined in claim (12) and, -at least one antibody selected from an anti-PD1antibody, an anti-CTLA4 antibody, an anti-PD-L1 antibody and a mixture of two or more thereof. The invention also relates to a compound of general formula (I) as defined in claim (17) for use in the treatment of cancer, said cancer being preferably selected from melanoma, bladder, kidney, prostate, colon, lung, breast and blood cancer.
本发明涉及一种通式(I)的化合物:所述化合物如权利要求(1)所定义。该发明还涉及一种药物组合物,包括: -如权利要求(12)中定义的通式(I)的化合物,以及 -至少一种
抗体,选自抗PD1
抗体、抗CT
LA4
抗体、抗PD-L1
抗体以及两种或更多种
抗体的混合物。该发明还涉及一种通式(I)如权利要求(17)所定义的化合物,用于治疗癌症,所述癌症优选选择自
黑色素瘤、膀胱、肾脏、前列腺、结肠、肺、乳腺和血液癌症。